Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review

Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review

Background: The landscape of systemic therapies for advanced non-melanoma skin cancers has been revolutionized by the advent of immunotherapy. Cemiplimab is the only immune checkpoint inhibitor (ICI) approved by the European Medicine Agency for recurrent/metastatic cutaneous squamous cell carcinoma...

Full description

Bibliographic Details
Main Authors: Marco Banini, Viola Salvestrini, Alessandra Vultaggio, Margherita Perlato, Valentina Mecheri, Cecilia Cerbai, Vieri Scotti, Andrea Matucci, Monica Mangoni, Lorenzo Livi, Pierluigi Bonomo
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Current Oncology
Subjects:
cutaneous squamous cell carcinoma
Cemiplimab
drug-related infusion reaction
drug desensitization
Online Access:https://www.mdpi.com/1718-7729/30/7/491

Internet

https://www.mdpi.com/1718-7729/30/7/491

Similar Items